Charles Rudin
Co-Director, Druckenmiller Center for Lung Cancer Research · New York Presbyterian Hospital
Credentials: · · · · · ·
History
PresentDruckenmiller Center for Lung Cancer Research · New York Presbyterian Hospital
- Present
Thoracic Oncology Service Division · New York Presbyterian Hospital
- Present
Cancer Center · New York Presbyterian Hospital
- 1996–1998
Research
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 7,953 citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs
JAMA · 2014 · 1,437 citations
- MK
63 papers
- NR
63 papers
- GR
57 papers
- ML
56 papers
- MH
42 papers · 1 as a fellow
- HY
41 papers
- AD
38 papers
- BL
36 papers
Grants
- 1997–2030
National Cancer Institute · P30
Contact PI · $13.1M · Sloan-Kettering Inst Can Research
- 2021–2028
Novel Therapeutic Development for Small Cell Lung Cancer
National Cancer Institute · R35
Contact PI · $6.3M · Sloan-Kettering Inst Can Research
- 2021–2027
Drivers of Histologic Transformation in EGFR-Mutant Lung Cancer
National Cancer Institute · R01
PI · $2M · Sloan-Kettering Inst Can Research
- 2017–2027
Coordinating Center for the NCI Small Cell Lung Cancer Research Consortium
National Cancer Institute · U24
Contact PI · $12.9M · Sloan-Kettering Inst Can Research
Clinical trials
- 2025–2029
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
- 2019–2023
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
Principal investigator · Terminated · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
- 2014–2015
Principal investigator · Completed · Phase 1, Phase 2
ECOG-ACRIN Cancer Research Group
- 2012–2027
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)